Aug. 18 at 7:40 PM
$INO What is confirmed and very Bullish:
* PDUFA target: October 30, 2026 .
* Late-cycle review meeting completed.
* All scheduled pre-licensure inspections completed.
* FDA review is continuing under the accelerated-approval program.
* Q2 operating expenses were
$18.6M, down 19% YoY.
* July offering generated ~
$18.3M net proceeds .
* Management expects cash resources to fund operations into late Q1 2027, including a potential INO-3107 launch if approved.
* As of today, August 18, October 30 is 73 days away, or about 10½ weeks.
